Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

Purpose: The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma were published previously. This report presents overall survival (OS) and efficacy accordin...

Full description

Saved in:
Bibliographic Details
Main Authors: Fukuoka M., Wu Y., Thongprasert S., Sunpaweravong P., Leong S., Sriuranpong V., Chao T., Nakagawa K., Chu D., Saijo N.
Format: Journal
Published: 2017
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79960702788&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/43028
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University

Internet

https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=79960702788&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/43028

Similar Items